The Chinese Biopharmaceutical company Sinovac Biotech has built CoronaVac, an inactivated-virus vaccine using a non-infectious variant of the virus causing the disease, unable to infect but capable of triggering an immune response.

The results of phase III of the clinical trial, presented on the 5th of February, started on 21 July 2020 in Brazil, Turquey, Indonesia, and Chile, grouping 25.000 participants. The results indicated a 91,25% efficacy.

CoronaVac consists of 2-dose series that are administered with 14 days difference. Almost twenty countries mainly distributed between Latin America and Asia are immunising their population with this vaccine.

The most common side effect, according to the researchers, is pain at the injection site.

CoronaVac vaccine can be stored at a temperature between 2ºC and 8ºC for three years.

We are a team of young journalists from Barcelona who work independently to combat misinformation in our territory and beyond. We rely on facts and data to verify what politicians say and the falsehoods circulating on social media.

We need you. With your contribution, you will contribute to a healthier political debate and help promote educational projects to teach citizens how to navigate information chaos and defend themselves against misinformation.

You can contribute as much as one euro and it won't take you more than 45 seconds (we've counted them). If you can, please mark your contribution as monthly and so we can continue to do our job rigorously and independently. Thank you so much.